Perez Matthew C, Zager Jonathan S, Amatruda Thomas, Conry Robert, Ariyan Charlotte, Desai Anupam, Kirkwood John M, Treichel Sheryl, Cohan David, Raskin Leon
Moffitt Cancer Center, Tampa, FL 33612, USA.
Minnesota Oncology, Fridley, MN 55432, USA.
Melanoma Manag. 2019 Jul 3;6(2):MMT19. doi: 10.2217/mmt-2019-0012.
Talimogene laherparepvec (T-VEC) is an intralesional treatment for unresectable cutaneous, subcutaneous and nodal melanoma. COSMUS-1 was conducted to examine how T-VEC is used in US clinical practice.
MATERIALS & METHODS: A chart review was conducted at seven centers, with 78 patients screened and 76 eligible.
Patients began treatment with T-VEC between October 2015 and December 2016. Median follow-up was 9.4 months. Twenty percent of patients (n = 15) completed T-VEC treatment with no remaining injectable lesions or pathologic complete response. Flu-like symptoms were the most commonly reported adverse events (n = 8; 10.5%), followed by lesion ulceration (n = 4; 5.3%). No herpetic lesions or infections were reported.
T-VEC was well tolerated and showed clinical utility.
talimogene laherparepvec（T-VEC）是一种用于不可切除的皮肤、皮下和淋巴结黑色素瘤的瘤内治疗药物。开展COSMUS-1研究以考察T-VEC在美国临床实践中的使用情况。
在七个中心进行了一项病历回顾，共筛查78例患者，76例符合条件。
患者于2015年10月至2016年12月开始接受T-VEC治疗。中位随访时间为9.4个月。20%的患者（n = 15）完成了T-VEC治疗，且无剩余可注射病灶或病理完全缓解。流感样症状是最常报告的不良事件（n = 8；10.5%），其次是病灶溃疡（n = 4；5.3%）。未报告疱疹病灶或感染。
T-VEC耐受性良好且具有临床应用价值。
